Trial Profile
An open-label, prospective, comparative trial to assess prostate specific antigen progression on bicalutamide monotherapy versus bicalutamide and dutasteride therapy in patients with advanced and/or metastatic carcinoma of the prostate.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2012
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Dutasteride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms AVOCAT
- 01 Apr 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 05 Feb 2009 Status changed from not stated to recruiting.
- 04 Feb 2009 The number of trial centres changed from 2 to 3.